Sparse batch of recommendations at EMA/CHMP February meeting

28 February 2020

At its February 24-27 meetings, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended two medicines for approval at its February 2020 meeting.

The Committee recommended granting a marketing authorization for Fetcroja (cefiderocol) from Japan’s Shionogi (TYO: 4507) for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.

The generic medicine Tigecycline Accord (tigecycline) from Accord Healthcare received a positive opinion for the treatment of complicated skin and soft tissue (ie, tissues just below the skin) infections and complicated intra-abdominal infections.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK